↓ Skip to main content

Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men

Overview of attention for article published in The Journal of Clinical Endocrinology & Metabolism, December 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 11,067)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
263 news outlets
blogs
28 blogs
twitter
323 tweeters
facebook
20 Facebook pages
googleplus
1 Google+ user
video
16 video uploaders

Citations

dimensions_citation
25 Dimensions

Readers on

mendeley
183 Mendeley
Title
Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men
Published in
The Journal of Clinical Endocrinology & Metabolism, December 2016
DOI 10.1210/jc.2016-2141
Pubmed ID
Authors

Hermann M. Behre, Michael Zitzmann, Richard A. Anderson, David J. Handelsman, Silvia W. Lestari, Robert I. McLachlan, M. Cristina Meriggiola, Man Mohan Misro, Gabriela Noe, Frederick C. W. Wu, Mario Philip R. Festin, Ndema A. Habib, Kirsten M. Vogelsong, Marianne M. Callahan, Kim A. Linton, Doug S. Colvard

Abstract

The development of a safe and effective reversible method of male contraception is still an unmet need. Evaluation of suppression of spermatogenesis and contraceptive protection by coadministered im injections of progestogen and testosterone. Prospective multicentre study. Ten study centers. Healthy men, aged 18-45 years, and their 18- to 38-year-old female partners, both without known fertility problems. Intramuscular injections of 200-mg norethisterone enanthate combined with 1000-mg testosterone undecanoate, administered every 8 weeks. Suppression of spermatogenesis by ejaculate analysis, contraceptive protection by pregnancy rate. Of the 320 participants, 95.9 of 100 continuing users (95% confidence interval [CI], 92.8-97.9) suppressed to a sperm concentration less than or equal to 1 million/mL within 24 weeks (Kaplan-Meier method). During the efficacy phase of up to 56 weeks, 4 pregnancies occurred among the partners of the 266 male participants, with the rate of 1.57 per 100 continuing users (95% CI, 0.59-4.14). The cumulative reversibility of suppression of spermatogenesis after 52 weeks of recovery was 94.8 per 100 continuing users (95% CI, 91.5-97.1). The most common adverse events were acne, injection site pain, increased libido, and mood disorders. Following the recommendation of an external safety review committee the recruitment and hormone injections were terminated early. The study regimen led to near-complete and reversible suppression of spermatogenesis. The contraceptive efficacy was relatively good compared with other reversible methods available for men. The frequencies of mild to moderate mood disorders were relatively high.

Twitter Demographics

The data shown below were collected from the profiles of 323 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 183 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 3 2%
United Kingdom 1 <1%
Unknown 179 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 53 29%
Student > Master 37 20%
Student > Ph. D. Student 25 14%
Researcher 19 10%
Unspecified 14 8%
Other 35 19%
Readers by discipline Count As %
Medicine and Dentistry 59 32%
Nursing and Health Professions 20 11%
Unspecified 20 11%
Agricultural and Biological Sciences 20 11%
Biochemistry, Genetics and Molecular Biology 16 9%
Other 48 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 2541. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2019.
All research outputs
#395
of 13,250,737 outputs
Outputs from The Journal of Clinical Endocrinology & Metabolism
#1
of 11,067 outputs
Outputs of similar age
#15
of 287,779 outputs
Outputs of similar age from The Journal of Clinical Endocrinology & Metabolism
#1
of 183 outputs
Altmetric has tracked 13,250,737 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,067 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 287,779 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 183 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.